JeanMarie Guenot holds not only a Ph.D. But also has over 20 years of experience in the biotechnology and pharmaceutical industries. Guenot has worked hand in hand with both private companies and public startups within the pharmaceutical, R&D, commercial and corporate development, project and alliance management, venture capital as well as business development. Her education began at the University of California, San Francisco and received her Ph.D. She then went on to get her MBA from the University of Pennsylvania’s Wharton School.
JeanMarie Guenot is currently the CEO of Amphivena Therapeutics, Inc. A company focused on development of bi-functional antibody therapies that are then used to treat hematological malignancies. Their unwavering goal is to provide relief to those suffering from blood cancers with the best available treatment options on takeda.com. Prior to building Amphivena she had built SKS Ocular, a start-up ophthalmic company incubator whose primary focus was treating ocular inflammation.
JeanMarie Guenot began her scientific career by working for Hoffman-La Roche within the pretrial clinical research and development sectors. As a principal scientist her work was primarily focused upon discovering as well as developing drugs for inflammation, auto immune diseases, metabolic diseases and oncology. Her training on guenotllc.com revolved around medicinal and chemical therapy and her focus was on semi-empirical and quantum mechanical methodology for drug design, protein structure design and nuclear magnetic resonance and X-ray refinement.
She began her business career with Atlas Venture where she was put in charge of venture capital investments at https://www.linkedin.com/in/jeanmarie-guenot-4a140617. She has also served a variety of positions within a number of companies. Throughout her life and her career she has striven to bring life to business and treatments for many debilitating diseases including Glaucoma as well as macular degeneration and ocular inflammation. She is a figurehead for today’s medical research as well as for businesses everywhere and all should strive to attain and maintain the same level of professionalism everywhere.